AstraZeneca Pharma India Limited — Important, 07-03-2025: Updates

AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation to import and sell Durvalumab solution for infusion (Imfinzi) in India for an additional indication. This approval expands the drug's usage to treat patients with limited-stage small cell lung cancer who have not experienced disease progression after platinum-based chemoradiation therapy. The marketing of Durvalumab for this new indication is subject to obtaining any necessary statutory approvals. This development highlights potential growth opportunities in the oncology segment, which could positively impact AstraZeneca's market position and overall performance. Shareholders should monitor this advancement as it may enhance revenue streams from the treatment portfolio.